Recro

Evolus & Urovant: Similar Strategies, Opposite Reactions to Positive Catalysts
Gallery
Evolus & Urovant: Similar Strategies, Opposite Reactions to Positive Catalysts

Bill Langbein, Case Study, Education, Healthcare, Insights, Pharmaceutical & Biotechnology

Evolus & Urovant: Similar Strategies, Opposite Reactions to Positive Catalysts

By Bill Langbein|2019-03-25T11:45:49-04:00March 25th, 2019|Categories: Bill Langbein, Case Study, Education, Healthcare, Insights, Pharmaceutical & Biotechnology|Tags: biotech, Botox, Recro, REPH, SanaCurrents|

One of the strongest performing biopharmaceutical stocks this year is [...]

0

Recro To Consider Dispute Resolution With FDA After Complete Response Letter
Gallery
Recro To Consider Dispute Resolution With FDA After Complete Response Letter

Bill Langbein, Healthcare, Insights, Pharmaceutical & Biotechnology, SanaCurrents

Recro To Consider Dispute Resolution With FDA After Complete Response Letter

By Bill Langbein|2020-03-30T10:13:30-04:00March 24th, 2019|Categories: Bill Langbein, Healthcare, Insights, Pharmaceutical & Biotechnology, SanaCurrents|Tags: Complete Response Letter, CRL, Recro, REPH|

Shares of Recro Pharma, Inc. (NASDAQ:REPH) likely will fall in [...]

0

SSL